The information within this section of the website is intended for UK Healthcare Professionals. UK Practice Managers should follow the relevant links.

Picked for heritage and experience

Considerations2,3

• In order to ensure adequate ovarian suppression in pre- and perimenopausal women, administer leuprorelin for at least 6-8 weeks prior to commencement of an aromatase inhibitor and on schedule without interruption throughout aromatase inhibitor treatment to avoid rebound increases in circulating estrogens in premenopausal women

• Following chemotherapy and before commencement of leuprorelin, confirm premenopausal status by blood concentrations of estradiol and FSH, to avoid unnecessary treatment in the event of chemotherapy-induced menopause

• Following commencement of leuprorelin and prior to aromatase inhibitor treatment, confirm ovarian suppression by assessment of circulating FSH and estradiol and repeat every 3 months during combination treatment

• Discontinue aromatase inhibitors within 1 month of the last Prostap SR DCS administration and within 3 months of the last Prostap 3 DCS administration

• Check relevant safety information of co-administered products

• Assess bone mineral density before starting treatment and monitor and treat for osteoporosis when appropriate

• Risk of musculoskeletal disorders when a GnRH agonist is used in combination with either an aromatase inhibitor or tamoxifen

• Hypertension has been reported. Monitor cardiovascular risk factors, blood pressure, hyperglycaemia and diabetes regularly in premenopausal women with breast cancer receiving GnRH in combination with exemestane or tamoxifen.

• Monitor patients with depression or depression history

• Patients should notify physician if regular menstruation persists

A full list of adverse events, special warnings and precautions are listed in the Prostap DCS summary of product characteristics

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. Takeda UK Ltd. Data on file, DF120604(2).
  2. Prostap SR DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  3. Prostap 3 DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  4. Health and Safety Executive. Health and Safety (Sharp Instruments in Healthcare) Regulations 2013. Available via: www.hse.gov.uk/pubns/hsis7.pdf (last accessed May 2019).
  5. European Agency for Safety and Health at Work. Directive 2010/32/EU – prevention from sharp injuries in the hospital and healthcare sector. Available at: www.osha.europa.eu/en/legislation/directives/council-directive-2010-32-eu-prevention-from-sharp-injuries-in-the-hospital-and-healthcare-sector (last accessed May 2019).
  6. Ogawa Y et al. J Pharm 1989;41(7):439-44.
  7. Abouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513-26.
  8. The Leuprolide Study Group. N Eng J Med 1984;311:1281-6.
  9. Friedman AJ et al. Fertil Steril 1987;48(4):560-4.
  10. PharmaTimes online. Takeda launces new presentation of Prostap, 2011. Available at: http://www.pharmatimes.com/news/takeda_launches_new_presentation_of_prostap_980760 (last accessed May 2019).
  11. National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and management. NICE guideline (CG175).
  12. Goel S et al. Cochrane Database Syst Rev 2009;7(4):CD004562.
  13. Cancer Research UK. Hormone therapy for cancer, June 2017. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/hormone-therapy/for-cancer (last accessed May 2019).
  14. NHS UK. Breast cancer in women – Treatment, September 2016. Available at: https://www.nhs.uk/conditions/breast-cancer/treatment/ (last accessed May 2019).
  15. Zoladex 3.6 mg. AstraZeneca UK. Summary of Product Characteristics. Available at: www.medicines.org.uk
  16. Decapeptyl SR 3 mg. Ipsen Ltd. Summary of Product Characteristics. Available at: www.medicines.org.uk

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers. If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a Practice Manager

Yes

I am a Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a
Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

Yes

I am a Healthcare Professional interested in breast cancer

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.